ALS News Today

ALS News Today is a daily online news platform dedicated to keeping ALS patients and their caregivers informed about the newest scientific research and advancements related to the disease. Despite ongoing research and development efforts in ALS treatment, health media often overlooks this important information. To address this gap, ALS News Today employs a skilled team of researchers and journalists who gather the latest news on ALS and present it in an accessible way for patients.

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#613873

United States

#288321

Health/Health Conditions and Concerns

#791

Traffic sources

Monthly visitors

Articles

Treatment with jacifusen shows benefits for some people with FUS-ALS

5 days ago | alsnewstoday.com | Marisa Wexler

Treatment with the experimental therapy jacifusen was generally well tolerated and appeared to slow or even reverse disease progression in some people with amyotrophic lateral sclerosis (ALS) caused by mutations in the FUS gene. That’s according to data from 12 people who received the therapy as part of an expanded access program. Data from these cases also indicate jacifusen decreased nerve damage.
Transposon's TPN-101 selected for testing in HEALEY ALS trial

6 days ago | alsnewstoday.com | Margarida Maia

Oral small molecule TPN-101 has been selected for testing in amyotrophic lateral sclerosis (ALS) as part of the HEALEY ALS platform trial. The decision to include TPN-101 in the platform trial (NCT04297683) was based on the treatment’s unique mechanism of action and final data from a Phase 2 clinical trial (NCT04993755) in adults with ALS or frontotemporal dementia (FTD) related to C9orf72 mutations, developer Transposon Therapeutics said.
Adapting helped us keep the outdoors a part of life with ALS

1 week ago | alsnewstoday.com | Juliet Taylor

My late husband, Jeff, and I shared a love of the outdoors, even though our preferred activities were often different. I loved to hike and kayak, while Jeff, who’d been injured when a car hit his bicycle in 2010 and still suffered from orthopedic pain, preferred to relax. Whether at home or traveling, many evenings found him outside with a cigar, a beer, and music playing quietly on a portable speaker.
Mitochondrial abnormalities seen early in many forms of ALS: Study

1 week ago | alsnewstoday.com | Marisa Wexler

A study found that genetic mutations associated with amyotrophic lateral sclerosis (ALS) lead to problems with the function and transport of mitochondria, cellular structures needed for energy production, early in the disease course, before abnormal protein clumps are formed.
FDA clears Phase 3b trial of NurOwn for ALS

2 weeks ago | alsnewstoday.com | Margarida Maia

The U.S. Food and Drug Administration (FDA) has cleared a Phase 3b clinical trial to test Brainstorm Cell Therapeutics’ cell-based therapy NurOwn (debamestrocel) in people with amyotrophic lateral sclerosis (ALS). The trial, ENDURANCE (NCT06973629), is expected to open soon at more than a dozen sites across the U.S. It plans to recruit about 200 adults with moderate disease who have been experiencing symptoms of ALS, including muscle weakness, for less than two years.
Just what does coping mean when you're living with ALS?

2 weeks ago | alsnewstoday.com | Kristin Neva

My husband, Todd, hasn’t left our home since a dentist appointment last fall, and he hasn’t been to the park or attended an event in years. He doesn’t want to go out — his ALS progression has made being anywhere outside the house too uncomfortable to enjoy. He’s most at ease in his office, set up on his computer. I understand where he’s coming from. When I’m sick with a bad cold or the flu, there’s no place I’d rather be than home.
Survival in ALS may improve by adding low-dose IL-2 to riluzole treatment

2 weeks ago | alsnewstoday.com | Marisa Wexler

Adding a low dose of the anti-inflammatory molecule interleukin-2 (IL-2) to treatment with riluzole is safe and may help extend survival in certain people with amyotrophic lateral sclerosis (ALS), according to findings from a clinical trial called MIROCALS. The Phase 2b trial didn’t show a significant survival benefit in the overall population and failed to meet its main goal.
Bacteria mix to aid gut microbiome may slow ALS progression

2 weeks ago | alsnewstoday.com | Margarida Maia

MaaT033, an oral therapy aiming to restore balance to the collection of bacteria and other microbes in the gut, was safe and well tolerated after three months and showed signs of slowing amyotrophic lateral sclerosis (ALS) progression, according to new data from a pilot Phase 1b trial. The IASO study (NCT05889572) was designed to test how safe and well tolerated Maat Pharma‘s MaaT033 is when taken as a capsule over 84 days, or nearly three months.
Slow-progressing ALS patients see gains in function, survival with Neuronata-R

2 weeks ago | alsnewstoday.com | Andrea Lobo

Neuronata-R (lenzumestrocel), an investigational stem cell therapy from Corestemchemon significantly improved function and reduced markers of nerve cell damage in a subgroup of people with slow-progressing amyotrophic lateral sclerosis (ALS), the final results of a Phase 3 clinical trial show. The ALSummit trial (NCT04745299) failed to meet its primary goal — a combined assessment of function and survival known as CAFS — in the overall study population.
Why sharing is important amid the sadness of May

3 weeks ago | alsnewstoday.com | Juliet Taylor

I remember the emptiness I felt the first September after graduating from college. I’d been a student for 16 of my 21 years at that time, and the void of not going back to school at the end of summer was disconcerting. For some years after that, I quietly regarded September as a symbol of unwelcome change and even loss. It was my first time experiencing sadness related to a certain time of year.